All News
Filter News
Found 808,898 articles
-
NanoVibronix Provides Update on Expanding Access to PainShield
1/18/2023
NanoVibronix, Inc. (NASDAQ: NAOV) (the “Company”), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today provided an update on the efforts to expand access to the Company’s PainShield product.
-
Medigene Receives $3 Million Milestone Payment from 2seventy bio
1/18/2023
Medigene AG announced that it has received a $3 million milestone payment from its partner 2seventy bio as part of its T cell receptor agreement in cancer immunotherapy, and which may lead to further potential milestone payments in the future.
-
Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock - Jan 18, 2023
1/18/2023
Deciphera Pharmaceuticals, Inc. announced that it intends to offer and sell $125,000,000 of shares of its common stock in an underwritten public offering.
-
IRADIMED CORPORATION Announces Preliminary Financial Results for Fourth Quarter 2022
1/18/2023
IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced selected preliminary financial results for the fourth quarter that ended December 31, 2022.
-
SQZ Biotechnologies Receives Notice Regarding Continued Listing Standards From the New York Stock Exchange
1/18/2023
SQZ Biotechnologies announced that on January 18, 2023, it received notice from the New York Stock Exchange indicating that the Company is not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company’s common stock was less than $1.00 over a consecutive 30 trading-day period.
-
Proxima Clinical Research Named to Inc. Best in Business List
1/18/2023
Proxima Clinical Research is proud to announce it has been named to the Inc. Best in Business list in the Business Services category.
-
Pasithea Therapeutics Signs CMC Development and Manufacturing Agreement for the Production of PAS-004
1/18/2023
Pasithea Therapeutics Corp. today announced its contract with WuXi STA, a subsidiary of WuXi AppTec, to manufacture the active pharmaceutical ingredient (“API”) for Pasithea’s macrocyclic, next-generation MEK Inhibitor, PAS-004 (formerly CIP-137401).
-
Agilent Included in Just Capital’s 2023 List of Most Just Companies
1/18/2023
Ranking Underscores Agilent’s Strong Performance on Issues of Greatest Importance to Americans Agilent Technologies Inc. is ranked 35 among the top 100 Most JUST companies, the fifth year the company has been included in the annual list by Just Capital and CNBC.
-
Freenome Partners With Geisinger for the Sanderson Study
1/18/2023
Freenome, a privately held biotech company, announced that Pennsylvania-based Geisinger is joining as a study partner for the Sanderson Study, a study for the detection of multiple cancers that pairs multiomics with real-world data.
-
SAB Biotherapeutics Receives an Additional $8.2 Million in Closeout of DoD Contract
1/18/2023
SAB Biotherapeutics announced today that the company has received an additional $8.2 million from the U.S. Department of Defense (DoD) related to the closeout of the discontinued COVID-19 prototype research.
-
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Jan 18, 2023
1/18/2023
Neuronetics, Inc. announced the granting of inducement awards to three new non-executive employees.
-
Adolore Biotherapeutics to Present at the Virtual Investor 2023 Companies to Watch Event
1/18/2023
Adolore Biotherapeutics, Inc. announced that Roelof Rongen, CEO of Adolore, will present at the Virtual Investor 2023 Companies to Watch Event on Thursday, January 19, 2023 at 10:00 AM ET.
-
NeuroBo Pharmaceuticals Appoints Joseph Hooker as Interim Chief Executive Officer and President
1/18/2023
NeuroBo Pharmaceuticals, Inc. today announced that it has appointed Joseph Hooker as Interim Chief Executive Officer and President.
-
Sensorium Therapeutics Appoints Jeffrey M. Brown as Chief Scientific Officer
1/18/2023
Sensorium Therapeutics today announced the appointment of Jeffrey M. Brown, Ph.D., MBA as Chief Scientific Officer.
-
CXL Ophthalmics Appoints Jonathan Talamo, MD, as Chair of the Board
1/18/2023
CXL Ophthalmics, Inc., a clinical-stage company developing a minimally-invasive treatment for keratoconus, announced that Jonathan Talamo, MD has been appointed as its new Chair of the Board of Directors.
-
Exegenesis Bio Announces FDA Clearance of Investigational New Drug (IND) Application for EXG102-031; A Novel Gene Therapy for the Treatment of neovascular Age-Related Macular Degeneration (nAMD)
1/18/2023
Exegenesis Bio, a rapidly growing global gene therapy company is pleased to announce that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for EXG102-031.
-
RevBio Receives Approval to Start a Dental Clinical Trial in Italy for its Regenerative Biomaterial
1/18/2023
RevBio, Inc., announced that it has received approval from the Italian Ministry of Health and the Ethics Committee of the University “G.D'Annunzio” of Chieti-Pescara to start a 15-patient pilot clinical trial.
-
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 18, 2023
1/18/2023
Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced the grant of 96,700 restricted stock units to four new employees.
-
First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 2 Trial for the Treatment of Gaucher Disease in China
1/18/2023
CANbridge Pharmaceuticals, Inc. (1228.HK) announced that the first patient has been dosed in the Phase 2 part of the ongoing CAN103 Phase 1/2 trial in treatment-naïve patients with Gaucher disease (GD) Types I and III in China.
-
PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to Treat Rett Syndrome
1/18/2023
PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, is pleased to announce that it has applied with the U.S. Food and Drug Administration (“FDA”) to receive Orphan Drug Designation (“ODD”) for ketamine to treat Rett Syndrome, a rare genetic neurological disorder.